<DOC>
	<DOCNO>NCT02124148</DOCNO>
	<brief_summary>The main purpose study investigate safety prexasertib combination anti-cancer drug ( cisplatin , cetuximab , pemetrexed , fluorouracil LY3023414 ) participant advanced cancer cancer spread another part body . The study multiple part ( A , B , C , D E ) . Participants enroll one part .</brief_summary>
	<brief_title>A Study Prexasertib ( LY2606368 ) With Chemotherapy Targeted Agents Participants With Advanced Cancer</brief_title>
	<detailed_description>The primary purpose Parts A , B , C , D E study determine recommend dose level schedule prexasertib ( inhibitor checkpoint kinase 1 2 [ CHK1/CHK2 ] combination : - cisplatin ( Part A ) - cetuximab ( Part B ) - pemetrexed ( Part C ) - fluorouracil ( Part D ) - LY3023414 ( Part E ) [ An inhibitor phosphoinositide 3-kinase alpha ( PI3K alpha ) mammalian target rapamycin ( mTOR ) , DNA-dependent protein kinase ( DNA-PK ) , class I phosphoinositide 3-kinase ( PI3K ) family member ] participant advance metastatic cancer . Part A dose expansion study evaluate safety toxicity prexasertib recommend dose level combination cisplatin participant advance metastatic cancer , Part B dose expansion study evaluate safety toxicity prexasertib recommend dose level combination cetuximab participant advance metastatic colorectal cancer , Part C dose expansion study evaluate safety toxicity prexasertib recommend dose level combination pemetrexed participant advanced metastatic cancer , Part D dose expansion study evaluate safety toxicity prexasertib recommend dose level combination fluorouracil ( 5-FU ) participant advance metastatic cancer Part E dose expansion study evaluate safety toxicity prexasertib recommend dose level combination LY3023414 participant advance metastatic cancer . In Parts A B effect add granulocyte colony stimulate factor ( G-CSF ) cisplatin combination prexasertib cetuximab combination prexasertib explore . In Part A effect change schedule prexasertib cisplatin also explore .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Must appropriate candidate experimental therapy , determine investigator , available standard therapy fail Have adequate organ function Prior Therapies : Systemic treatment : must discontinue previous systemic treatment cancer recover acute effect therapy . Participants must discontinue mitomycinC nitrosourea therapy least 42 day discontinue cytotoxic therapy least 28 day prior study enrollment . Radiation therapy surgery : must complete least 4 week study enrollment All part except Part B dose expansion : Must diagnosis cancer advance metastatic Part B dose expansion : Must confirm Kirsten rat sarcoma viral oncogene homolog ( KRAS ) wildtype colorectal cancer metastatic recurrent fail oxaliplatin irinotecanbased chemotherapy intolerant irinotecan oxaliplatin Must available duration study willing follow study procedure If participant reproductive potential , must agree use medically approve contraceptive precaution study three month follow last dose study drug If participant female childbearing potential , must negative serum urine pregnancy test within 14 day first dose study drug must breast feeding Part E : Are able swallow capsule tablet Have receive 2 previous line cytotoxic chemotherapy ( receive cisplatin pemetrexed ) Must take unapproved drug treatment indication within last 28 day prior start study treatment Must active symptomatic fungal , bacterial viral infection , include human immunodeficiency virus ( HIV ) Hepatitis A , B , C Must serious heart condition , congestive heart failure , unstable angina pectoris , heart attack within last three month Must family history long QTc syndrome Must serotoninsecreting carcinoid tumor prior history druginduced serotonin syndrome Must acute leukemia Part E : Have insulindependent ( type I ) diabetes history gestational diabetes Part E : Prior treatment PI3K/mTOR inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cancer</keyword>
</DOC>